Lonza has shared results for the first quarter of 2016, its strongest first quarter ever recorded. The company’s successful performance was said to stem from its speciality ingredients sector.
Vitamin B3 solutions for cosmetics applications were said to accelerate demand in the speciality ingredients sector. Lonza said that the sector delivered “robust results” across all markets thanks to improved portfolio management and a focus on higher-value activities.
Looking ahead, Lonza said that it now expects “double-digit” growth for the first half of 2016, before tax. The strong growth was also said to have give the company a “healthy balance sheet” to support its improvement into the rest of 2016.
Richard Ridinger, CEO at Lonza, said: “These record-level results in the first quarter show that the strict market focus of our organisation is producing results. The ongoing improvement projects that emphasise organic growth, stringent portfolio management and operational excellence are proving to be successful. We will use this positive start to the year to drive further our transformation initiatives with the goal of further strengthening our position as a leading supplier to the pharmaceutical, biotech and our different speciality ingredients markets.”
Lonza supplies the pharmaceutical, healthcare and life science industries, including personal care and other consumer products.